JPRN-UMIN000002512
Completed
未知
Combined therapy with intravenous recombinant tissue plasminogen activator (rt-PA) and edaravone in the acute ischemic stroke patients within 3 hours of onset - Combined therapy with intravenous recombinant tissue plasminogen activator (rt-PA) and edaravone in the acute ischemic stroke patients within 3 hours of onset
Department of Stroke Medicine, Kawasaki Medical School0 sites100 target enrollmentDecember 1, 2009
ConditionsIscemic stroke
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Iscemic stroke
- Sponsor
- Department of Stroke Medicine, Kawasaki Medical School
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Diffusion weighted imaging evidence of significant early ischemic change 2\)Other exclusion criteria are same as Japan Alteplase Clinical Trial (J\-ACT) (stroke 2006;37:1810\) 3\)exclusion criteria of edaravone administraion mentioned in the package insert. Serume creatinine concentration over 1\.5mg/dl
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas. - NHL-ZNS-RezidivThe aim of the study is the prospective verification of effectiveness and compatibility of a systemic therapy with CNS passable cytostatics (high-dose Methotrexat and Ifosfamide, and high-dose Cytarabine and Thiothepa) combined with an intrathecal Depocyte therapy, followed by a High-dose dose chemotherapy with Carmustine, Thiothepa and Etoposid and an autologous stem cell transplantation.EUCTR2006-006516-30-DECharité-Universitätsmedizin Berlin
Completed
Not Applicable
Intravenous immunoglobulin therapy combined with Vitamins E and C for Kawasaki DiseaseKawasaki diseaseJPRN-UMIN000037134Fukuoka Children's Hospital Kawasaki disease center20
Completed
Phase 2
Alternative therapy using continuous intravenous administration of adrenomedullin for patients with inflammatory bowel diseaseinflammatory bowel diseaseJPRN-UMIN000003230First Department of Internal Medicine, Faculty of Medicine, University of Miyazaki10
Recruiting
Phase 3
Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patientschronic hepatitis type CJPRN-UMIN000005598Kyoto University Graduate School of Medicine Center for Genomic Medicine100
Completed
Not Applicable
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularizatioSubfoveal type 2 choroidal neovascularizationJPRN-UMIN000016870agoya City University Graduate School of Medicine20